Your Advocates Ltd’s Nautilus Biotechnolgy NAUT Stock Holding History

Your Advocates Ltd’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-150	Closed	-$582	–	230
2026 Q1	$582	Hold	150	–	–	﹤0.01%	205
2025 Q4	$293	Hold	150	–	–	﹤0.01%	216
2025 Q3	$126	Hold	150	–	–	﹤0.01%	207
2025 Q2	$108	Hold	150	–	–	﹤0.01%	192
2025 Q1	$129	Hold	150	–	–	﹤0.01%	199
2024 Q4	$252	Hold	150	–	–	﹤0.01%	191
2024 Q3	$428	Hold	150	–	–	﹤0.01%	209
2024 Q2	$351	Hold	150	–	–	﹤0.01%	212
2024 Q1	$441	Hold	150	–	–	﹤0.01%	206
2023 Q4	$449	Hold	150	–	–	﹤0.01%	211
2023 Q3	$474	Hold	150	–	–	﹤0.01%	243
2023 Q2	$581	Hold	150	–	–	﹤0.01%	247
2023 Q1	$416	Hold	150	–	–	﹤0.01%	222
2022 Q4	$270	Hold	150	–	–	﹤0.01%	211
2022 Q3	$0	Hold	150	–	–	﹤0.01%	211
2022 Q2	$0	Hold	150	–	–	﹤0.01%	222
2022 Q1	$1K	Hold	150	–	–	﹤0.01%	207
2021 Q4	$1K	Hold	150	–	–	﹤0.01%	191
2021 Q3	$1K	Hold	150	–	–	﹤0.01%	188
2021 Q2	$2K	Hold	150	–	–	﹤0.01%	128
2021 Q1	$2K	Buy	+150	New	+$2.08K	﹤0.01%	125

Other funds holding NAUT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Sentinel Trust Houston, Texas $1.13B AUM 24.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hillman Company Pittsburgh, Pennsylvania $283M AUM 23.82% 1-Year Est. Return

Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Your Advocates Ltd's NAUT Position: Q2 2026 in Review

Your Advocates Ltd sold out of Nautilus Biotechnolgy (NAUT) in Q2 2026, closing a stake of 150 shares — an estimated $582 sold.

Your Advocates Ltd first reported a position in NAUT in Q1 2021 and held it in 21 quarters. The position peaked at $2K in Q2 2021. 30 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

Your Advocates Ltd reported no remaining Nautilus Biotechnolgy position as of Q2 2026 after selling out during the quarter.
Your Advocates Ltd sold 150 Nautilus Biotechnolgy shares in Q2 2026, an estimated $582.
Your Advocates Ltd first reported a position in Nautilus Biotechnolgy in Q1 2021 and held it in 21 quarters.
Your Advocates Ltd's Nautilus Biotechnolgy position peaked at $2K in Q2 2021.
30 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Your Advocates Ltd's 13F filing for Q2 2026, filed 5 Aug 2026.